Kelly G Gwathmey1, Mark R Conaway2, Reza Sadjadi1, Amruta Joshi1, Carolina Barnett3, Vera Bril3, Eduardo Ng3, William David4, Karissa Gable5, Jeffrey T Guptill5, Lisa D Hobson-Webb5, Jennifer Dineen6, Michael Hehir7, Thomas H Brannagan8, Esther Byun9, Margaret Adler10, Ted M Burns1. 1. Department of Neurology, University of Virginia, P.O. Box 800394, Charlottesville, Virginia, 22908, USA. 2. Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia, USA. 3. Division of Neurology, Department of Medicine, The Ellen and Martin Prosserman Centre for Neuromuscular Diseases, University of Toronto and University Health Network, Toronto, Ontario, Canada, USA. 4. Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA. 5. Department of Neurology, Duke University Medical Center, Durham, North Carolina, USA. 6. Department of Neurology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, USA. 7. Department of Neurology, University of Vermont, Burlington, Vermont, USA. 8. Department of Neurology, Columbia University, New York, New York, USA. 9. Department of Neurology, Jerry L. Pettis VA Medical Center, Loma Linda, California, USA. 10. Department of Neurology, University of California, Los Angeles, California, USA.
Abstract
INTRODUCTION: Generic health-related quality-of-life (HRQOL) patient-reported outcome measures have been used in patients with chronic immune-mediated polyneuropathies. We have created a disease-specific HRQOL instrument. METHODS: The chronic acquired polyneuropathy patient-reported index (CAP-PRI) was developed and validated in multiple steps. Items were initially generated through patient and specialist input. The performance of the preliminary 20 items was analyzed via a prospective, 5-center study involving chronic immune-mediated polyneuropathy patients. RESULTS: Data analysis suggested modification to a 15-item scale with 3 response categories rather than 5. The final CAP-PRI was validated in another prospective, 5-center study. The CAP-PRI appeared to be a unidimensional outcome measure that fit the Rasch model in our multicenter cohort. It correlated appropriately with outcome measures commonly used in this patient population. CONCLUSIONS: The CAP-PRI is a simple disease-specific HRQOL measure that appears to be useful for clinical care and possibly also for clinical trials. Muscle Nerve 54: 9-17, 2016.
INTRODUCTION: Generic health-related quality-of-life (HRQOL) patient-reported outcome measures have been used in patients with chronic immune-mediated polyneuropathies. We have created a disease-specific HRQOL instrument. METHODS: The chronic acquired polyneuropathypatient-reported index (CAP-PRI) was developed and validated in multiple steps. Items were initially generated through patient and specialist input. The performance of the preliminary 20 items was analyzed via a prospective, 5-center study involving chronic immune-mediated polyneuropathypatients. RESULTS: Data analysis suggested modification to a 15-item scale with 3 response categories rather than 5. The final CAP-PRI was validated in another prospective, 5-center study. The CAP-PRI appeared to be a unidimensional outcome measure that fit the Rasch model in our multicenter cohort. It correlated appropriately with outcome measures commonly used in this patient population. CONCLUSIONS: The CAP-PRI is a simple disease-specific HRQOL measure that appears to be useful for clinical care and possibly also for clinical trials. Muscle Nerve 54: 9-17, 2016.
Authors: Ingemar S J Merkies; Richard A C Hughes; Peter Donofrio; Vera Bril; Marinos C Dalakas; Kim Hanna; Hans-Peter Hartung; Norman Latov; Pieter A van Doorn; Chunqin Deng Journal: J Peripher Nerv Syst Date: 2010-09 Impact factor: 3.494
Authors: R Hughes; S Bensa; H Willison; P Van den Bergh; G Comi; I Illa; E Nobile-Orazio; P van Doorn; M Dalakas; M Bojar; A Swan Journal: Ann Neurol Date: 2001-08 Impact factor: 10.422
Authors: Lidwine B Mokkink; Caroline B Terwee; Dirk L Knol; Paul W Stratford; Jordi Alonso; Donald L Patrick; Lex M Bouter; Henrica Cw de Vet Journal: BMC Med Res Methodol Date: 2010-03-18 Impact factor: 4.615
Authors: I S J Merkies; V Bril; M C Dalakas; C Deng; P Donofrio; K Hanna; H-P Hartung; R A C Hughes; N Latov; P A van Doorn Journal: Neurology Date: 2009-04-14 Impact factor: 9.910
Authors: Kelly G Gwathmey; Reza Sadjadi; William B Horton; Mark R Conaway; Carolina Barnett-Tapia; Vera Bril; James W Russell; Aziz Shaibani; Michelle L Mauermann; Michael K Hehir; Noah Kolb; Jeffrey Guptill; Lisa Hobson-Webb; Karissa Gable; Shruti Raja; Nicholas Silvestri; Gil I Wolfe; A Gordon Smith; Rabia Malik; Rebecca Traub; Amruta Joshi; Matthew P Elliott; Sarah Jones; Ted M Burns Journal: Neurology Date: 2018-05-04 Impact factor: 9.910
Authors: Karissa L Gable; Stojan Peric; Michael W Lutz; Ivo Bozovic; Milutin Petrovic; Aleksandar Stojanov; Ivana Basta; Jeffrey A Allen Journal: Brain Behav Date: 2022-07-21 Impact factor: 3.405